AdvanDx adds $8m to series C
This article was originally published in Clinica
AdvanDx, developer of molecular diagnostic tests for bacterial infections, has raised $8m in the second tranche of its series C financing round. The funds, which were provided by existing shareholders SLS Venture and LD Pensions, will be used to expand AdvanDx’s international sales and marketing activities and grow its product portfolio. In conjunction with the financing, the Woburn, Massachusetts firm also elected Tina Christensen to its board of directors. Ms Christensen is the vice-president and CFO of International Health Insurance danmark, a Danish health and medical travel insurance provider.